| Literature DB >> 23342380 |
Amy C Shurtleff1, Nicole Garza, Matthew Lackemeyer, Ricardo Carrion, Anthony Griffiths, Jean Patterson, Samuel S Edwin, Sina Bavari.
Abstract
We describe herein, limitations on research at biosafety level 4 (BSL-4) containment laboratories, with regard to biosecurity regulations, safety considerations, research space limitations, and physical constraints in executing experimental procedures. These limitations can severely impact the number of collaborations and size of research projects investigating microbial pathogens of biodefense concern. Acquisition, use, storage, and transfer of biological select agents and toxins (BSAT) are highly regulated due to their potential to pose a severe threat to public health and safety. All federal, state, city, and local regulations must be followed to obtain and maintain registration for the institution to conduct research involving BSAT. These include initial screening and continuous monitoring of personnel, controlled access to containment laboratories, accurate and current BSAT inventory records. Safety considerations are paramount in BSL-4 containment laboratories while considering the types of research tools, workflow and time required for conducting both in vivo and in vitro experiments in limited space. Required use of a positive-pressure encapsulating suit imposes tremendous physical limitations on the researcher. Successful mitigation of these constraints requires additional time, effort, good communication, and creative solutions. Test and evaluation of novel vaccines and therapeutics conducted under good laboratory practice (GLP) conditions for FDA approval are prioritized and frequently share the same physical space with important ongoing basic research studies. The possibilities and limitations of biomedical research involving microbial pathogens of biodefense concern in BSL-4 containment laboratories are explored in this review.Entities:
Mesh:
Year: 2012 PMID: 23342380 PMCID: PMC3528297 DOI: 10.3390/v4123932
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Laboratories with Active biosafety level 4 (BSL-4) Research Programs.
| Location (alphabetical by country) | Laboratory Name(s) |
|---|---|
| Geelong, Victoria, Australia | Australian Animal Health Laboratory, Commonwealth Science and Industrial Research Organization |
| Minsk, Belarus | Republican Research and Practical Center for Epidemiology and Microbiology |
| Winnipeg, Manitoba, Canada | National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health |
| Lyon, France | Jean Mérieux BSL-4 Laboratory, French National Institute for Health and Medical Research |
| Gabon, Africa | International Center for Medical Research, Franceville |
| Marburg, Germany | Philipps University of Marburg |
| Hamburg, Germany | Bernhard-Nocht Institute for Tropical Medicine |
| Bhopal, India | High Security Animal Disease Laboratory (HSADL) |
| Pune, India | National Institute of Virology |
| Moscow, Russia | Center for Virology, Sergiyev Posad |
| Koltsovo, Russia | Russia’s National Research Center of Virology and Biotechnology in Koltsovo (VECTOR) |
| Johannesburg, South Africa | Special Pathogens Unit, National Institute for Communicable Diseases |
| Solna, Sweden | Swedish Institute for Communicable Disease Control |
| Porton Down, Wiltshire, United Kingdom (UK) | Health Protection Agency (HPA) and the Defence Science and Technology Laboratory (Dstl) |
| Colindale, UK | Health Protection Agency's Centre for Infections |
| London, UK | National Institute for Medical Research |
| Potters Bar, UK | National Institute for Biological Standards and Control |
| Atlanta, Georgia, USA | Centers for Disease Control and Prevention |
| Fort Detrick, Maryland, United States of America (USA) | United States Army Medical Research Institute of Infectious Diseases (USAMRIID); NIAID — Integrated Research Facility (NIAID IRF); National Biodefense Analysis and Countermeasures Center (NBACC) |
| Galveston, Texas, USA | University of Texas Medical Branch at Galveston (UTMB) Shope Laboratory and Galveston National Laboratory (GNL) |
| Hamilton, Montana, USA | NIAID Integrated Research Facility (IRF) Rocky Mountain Laboratories (RML) |
| San Antonio, Texas, USA | Texas BioMedical Research Institute (Texas BioMed) |
Some commonly used chemical agents and methods of virus inactivation and decontamination.
| Inactivating agent | Chemical nature of inactivating agent | Method | Time to sample inactivation and removal from suite |
|---|---|---|---|
| Trizol® Reagents (Life Technologies, Grand Island, NY, USA), or similar [ | Phenol, guanidinium isothiocyanate | Mix one part sample to 3 parts Trizol®. Treat the threads of the vial with Trizol® before sealing. tube. | Immediate |
| Qiagen RNA lysis buffers [ | Guanidinium chloride plus ethanol or phenol | Mix one part sample to at least 3 parts lysis buffer. Treat the threads of the vial with buffer before sealing. | Immediate |
| Gamma irradiation [ | CO60 radiation | Placement of sample in irradiator and exposure to a known number of rads (e.g., 1 million or more) | Radiation treatment plus confirmatory safety testing on a sample must be completed |
| Heat, plus SDS sample buffer [ | Heat and denaturation by detergent | Boil sample for 5 minutes in 2%–4% SDS sample buffer | Immediate |
| 10% neutral buffered formalin (NBF) [ | Formaldehyde fixative | Submerge tissues, cell culture plates or samples on slides in formalin. Must be a 10:1 formalin to sample volume ratio, and any jar threads must be wiped with formalin upon sealing lids. Multiple exchanges of formalin buffer must occur for necropsy tissues. | Necropsy tissues must inactivate for 21 days. Cells on plastic culture dishes or slides must inactivate no less than 24 hours |
| 0.1%–1% glutaraldehyde, 4% paraformaldehyde with/out 1% osmium tetraoxide [ | Fixatives common to microscopy techniques | Immersion of sample in fluid, or exposure to vapors | At least 24 hours |
| Fresh 1:10 dilution of bleach | 5.25% sodium hypochlorite | Disinfectant for surfaces | Not a tissue or sample preparation reagent |
| Ethanol | 70% solution of ethanol | Disinfectant for surfaces | Not a tissue or sample preparation reagent |
| 5% Micro-Chem PlusTM (National Chemical Labs, Philadelphia, PA, USA) in water | Proprietary blend of dimethyl ammonium chlorides and polyethylene ether glycols | Disinfectant for surfaces, showers | Not a tissue or sample preparation reagent |
Methods involving live virus work have very few alternatives for performance at Biosafety level 2 (BSL-2).
| Method or Assay | Alternative |
|---|---|
| Live virus quantitation: | Any live virus quantification in samples must be done inside the suite. Plaque assays could be counted on photographs rather than inside the suite, but the assay must be performed entirely at BSL-4. Viral genomic burden in a sample can be measured by qRT-PCR. |
| Neutralization assay for antibody or chemical activity against virus | Plaque-reduction neutralization tests on native viruses must be done inside the suite. Use of BSL-2 pseudotyped or surrogate viruses, if available, could be substituted for testing antibody binding. |
| ELISA or plate-based assays using any reagent that is either live virus as substrate or capture antigen, or where the reagent (such as immune serum) under test could be potentially infectious | No immune serum can come out of the suite unless irradiated and safety tested. Irradiation may destroy serum proteins of interest before they can be assayed. |
| Flow cytometry on infected cells | Infected cells can be permeabilized and fixed in formalin and brought out for flow methods, provided that the antibody staining is not inhibited by the fixation. |
| Protein analysis methods | Some co-immunoprecipitation and native PAGE methods may require BSL-4 containment. |
| Cell culture based drug screening assays for antiviral activity | No alternative unless a pseudotyped or surrogate virus exists for use in screens. |
| Animal observations and veterinary assessments | No alternative, animals must be tended in person at BSL-4. |
| Quality Assurance audits supporting regulated (GLP) studies | No realistic alternative, most work cannot be closely audited from windows or security cameras. |
A wide variety of equipment exists at various BSL-4 laboratories for performance of sophisticated methods.
| Type of equipment | Example of equipment used |
|---|---|
| General Laboratory equipment | Class II and III biosafety cabinets |
| Specialized immunoassay equipment | Sector® Imager 6000 (Meso Scale Discovery) |
| Animal treatment or handling equipment | Telemetry, e.g., DSI JETTM (Data Sciences International) |
| Clinical chemistry and pathology instruments | Serum chemistry machines such as Vitros® (Ortho Clinical Dignostics) |
| Imaging instruments | Light boxes/digital camera setups |